Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Long-Term Deferred Tax: 2022-2024

  • ProQR Therapeutics N.V's Long-Term Deferred Tax fell 18.73% to $3.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.5 million, marking a year-over-year decrease of 18.73%. This contributed to the annual value of $3.5 million for FY2024, which is 19.17% down from last year.
  • ProQR Therapeutics N.V's Long-Term Deferred Tax amounted to $3.5 million in Q4 2024, which was down 18.73% from $4.3 million recorded in Q4 2023.
  • ProQR Therapeutics N.V's Long-Term Deferred Tax's 5-year high stood at $4.3 million during Q4 2023, with a 5-year trough of $3.5 million in Q4 2024.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $4.0 million (2022), whereas its average is $3.9 million.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Long-Term Deferred Tax grew by 7.13% in 2023, and later declined by 18.73% in 2024.
  • ProQR Therapeutics N.V's Long-Term Deferred Tax (Quarterly) stood at $4.0 million in 2022, then climbed by 7.13% to $4.3 million in 2023, then fell by 18.73% to $3.5 million in 2024.
  • Its last three reported values are $3.5 million in Q4 2024, $4.3 million for Q4 2023, and $4.0 million during Q4 2022.